{
    "Trade/Device Name(s)": [
        "LIAISON\u00ae VZV IgG",
        "LIAISON\u00ae Control VZV IgG"
    ],
    "Submitter Information": "DiaSorin Inc.",
    "510(k) Number": "K150375",
    "Predicate Device Reference 510(k) Number(s)": [
        "K061820"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFY",
        "JJX"
    ],
    "Summary Letter Date": "February 12, 2015",
    "Summary Letter Received Date": "February 13, 2015",
    "Submission Date": "February 12, 2015",
    "Regulation Number(s)": [
        "21 CFR 866.3900"
    ],
    "Regulation Name(s)": [
        "Varicella-zoster virus serological reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "serology"
    ],
    "Analyte(s)": [
        "IgG antibodies to varicella-zoster virus"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "LIAISON\u00ae Analyzer family",
        "LIAISON\u00ae XL"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescence immunoassay (CLIA)"
    ],
    "Methodologies": [
        "Indirect immunoassay",
        "Automated serological testing"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for DiaSorin LIAISON VZV IgG assay and control for qualitative detection of VZV IgG antibodies in human serum using CLIA technology",
    "Indications for Use Summary": "Aids in determination of previous infection of varicella-zoster virus by qualitative detection of specific IgG antibodies in human serum; controls used to monitor assay performance",
    "fda_folder": "Microbiology"
}